Souheil Khoukaz, MD
Interventional Cardiology · Festus, MONPI 1386636868
Payments from drug & device makers
Across 309 payments — averaging $30.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abiomed$976
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$611
- Abbott$575
- AstraZeneca$502
- E.r. Squibb & Sons, L.L.C.$397
- plus $3K from 32 others
What the payments were for
- Travel & lodging$1,79719%
- Food & beverage$7,63280%
- Education$631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 43 | $2,972 |
| Abiomed | 8 | $976 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 45 | $611 |
| Abbott | 29 | $575 |
| AstraZeneca | 12 | $502 |
| E.r. Squibb & Sons, L.L.C. | 17 | $397 |
| Novartis | 18 | $337 |
| Philips North America LLC | 4 | $336 |
| Pfizer | 21 | $327 |
| Amgen | 21 | $325 |
| Penumbra, Inc. | 2 | $237 |
| Johnson & Johnson | 15 | $236 |
| Boston Scientific | 9 | $231 |
| Sanofi-aventis U.S. LLC | 8 | $162 |
| Boehringer Ingelheim | 8 | $153 |
| Biotronik Inc. | 5 | $120 |
| Shockwave Medical, Inc | 3 | $92 |
| Regeneron Healthcare Solutions, Inc. | 5 | $90 |
| Intuitive Surgical | 1 | $75 |
| Actelion Pharmaceuticals US, Inc. | 1 | $75 |
| Merck | 5 | $70 |
| Cardiovascular Systems Inc. | 2 | $65 |
| Novo Nordisk | 3 | $58 |
| Amarin Pharma, Inc. | 4 | $54 |
| Stryker | 2 | $46 |
| Bayer | 2 | $45 |
| Siemens Medical Solutions USA, Inc. | 1 | $38 |
| ZOLL Circulation Inc | 2 | $38 |
| Edwards Lifesciences | 2 | $36 |
| Angiodynamics, Inc. | 1 | $33 |
| Gilead | 2 | $31 |
| Cvrx, Inc. | 1 | $30 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| United Therapeutics Corporation | 1 | $23 |
| Terumo Medical Corporation | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Micra$1,040
- Impella$841
- SelectSecure$586
- ATTAIN COMMAND + SUREVALVE$328
- (5044) MCOT$254
- Resolute$250
- FARXIGA$250
- Indigo System$237
- ONYX FRONTIER$136
How this compares
$9,492 in reported general payments places this provider in the 40th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 373 | $414,234 |
| JardianceEmpagliflozin | 183 | $176,627 |
| EntrestoSacubitril/Valsartan | 164 | $150,786 |
| XareltoRivaroxaban | 143 | $125,410 |
| Repatha SureclickEvolocumab | 128 | $108,554 |
| FarxigaDapagliflozin Propanediol | 56 | $63,083 |
| BrilintaTicagrelor | 46 | $33,253 |
| Praluent PenAlirocumab | 47 | $32,351 |
| MultaqDronedarone Hcl | 25 | $29,696 |
| Atorvastatin Calcium | 777 | $8,426 |
| VascepaIcosapent Ethyl | 19 | $8,181 |
| Carvedilol | 854 | $6,582 |
| Ranolazine ErRanolazine | 71 | $6,369 |
| Icosapent Ethyl | 12 | $6,025 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 526 | $4,978 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $327 | $414,234373 claims |
| Boehringer IngelheimJardiance | $153 | $176,627183 claims |
| NovartisEntresto | $337 | $150,786164 claims |
| Johnson & JohnsonXarelto | $236 | $125,410143 claims |
| AstraZenecaFarxiga, Brilinta | $502 | $96,335102 claims |
| Sanofi-aventis U.S. LLCMultaq | $162 | $29,69625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Festus
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
- Jasvindar SinghSaint Louis$993K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.